Abstract |
Human parvovirus B19 (B19) is a known cause of erythema infectiosum ( fifth disease) and aplastic crisis in patients with hemolytic anemias. When patients with malignant diseases are infected by B19 during chemotherapy, erythroid suppression of bone marrow sometimes occurs. We performed a retrospective investigation of B19 infection among 95 children with malignant diseases in our hospital during the past 14 years. By the method of dot blot hybridization, 9 of 95 patients were found to be positive for B19 DNA during chemotherapy. All 9 patients had reticulocytopenia at the time B19 DNA was detected in their serum samples. Neutropenia and thrombocytopenia were not found. Seven of them had only transient reticulocytopenia. Serum samples from 2 other patients were positive for B19 DNA for a longer time. They suffered from persistent anemia for about 2 and 13 month, respectively. The years when B19 DNA was detected from the 9 patients corresponded to the prevalence of erythema infectiosum in Japan.
|
Authors | Y Yoto, T Kudoh, N Suzuki, Y Matsunaga, S Chiba |
Journal | Acta haematologica
(Acta Haematol)
Vol. 90
Issue 1
Pg. 8-12
( 1993)
ISSN: 0001-5792 [Print] Switzerland |
PMID | 8237278
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
|
Topics |
- Child
- DNA, Viral
(blood)
- Enzyme-Linked Immunosorbent Assay
(methods)
- Erythema Infectiosum
(blood, epidemiology)
- Female
- Humans
- Immunoblotting
(methods)
- Japan
(epidemiology)
- Male
- Neoplasms
(blood, complications)
- Nucleic Acid Hybridization
(methods)
- Parvovirus B19, Human
(genetics)
- Polymerase Chain Reaction
(methods)
- Prevalence
- Retrospective Studies
|